119 related articles for article (PubMed ID: 29967074)
1. Stop fRETting the Target: Next-Generation RET Inhibitors Have Arrived.
Iams WT; Lovly CM
Cancer Discov; 2018 Jul; 8(7):797-799. PubMed ID: 29967074
[No Abstract] [Full Text] [Related]
2. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
3. Towards precision oncology in RET-aberrant cancers.
Subbiah V; Roszik J
Cell Cycle; 2017 May; 16(9):813-814. PubMed ID: 28318386
[No Abstract] [Full Text] [Related]
4. Progress and potential impact of RET kinase targeting in cancer.
Mulligan LM
Expert Rev Proteomics; 2016 Jul; 13(7):631-3. PubMed ID: 27337654
[No Abstract] [Full Text] [Related]
5. BLU-667 Targets RET-Altered Cancers.
Cancer Discov; 2018 Jun; 8(6):OF8. PubMed ID: 29657136
[TBL] [Abstract][Full Text] [Related]
6. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
7. RET kinase inhibitors: a review of recent patents (2012-2015).
Mologni L; Gambacorti-Passerini C; Goekjian P; Scapozza L
Expert Opin Ther Pat; 2017 Jan; 27(1):91-99. PubMed ID: 27646564
[TBL] [Abstract][Full Text] [Related]
8. Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?
Sundar R; Tan P
Cancer Discov; 2018 Jan; 8(1):14-16. PubMed ID: 29311223
[TBL] [Abstract][Full Text] [Related]
9. Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor.
Sun QZ; Xu Y; Liu JJ; Zhang CH; Wang ZR; Zheng RL; Wang WJ; Li LL; Yang SY
Mol Divers; 2014 May; 18(2):403-9. PubMed ID: 24515340
[TBL] [Abstract][Full Text] [Related]
10. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
11. 65 YEARS OF THE DOUBLE HELIX: Exploiting insights on the RET receptor for personalized cancer medicine.
Mulligan LM
Endocr Relat Cancer; 2018 Aug; 25(8):T189-T200. PubMed ID: 29743166
[TBL] [Abstract][Full Text] [Related]
12. Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition.
Subbiah V; Pal SK
Cancer Discov; 2019 Dec; 9(12):1646-1649. PubMed ID: 31792121
[TBL] [Abstract][Full Text] [Related]
13. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.
Han M; Li S; Ai J; Sheng R; Hu Y; Hu Y; Geng M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5679-5684. PubMed ID: 27815117
[TBL] [Abstract][Full Text] [Related]
16. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
De Falco V; Carlomagno F; Li HY; Santoro M
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene.
Mendes Oliveira D; Grillone K; Mignogna C; De Falco V; Laudanna C; Biamonte F; Locane R; Corcione F; Fabozzi M; Sacco R; Viglietto G; Malanga D; Rizzuto A
J Exp Clin Cancer Res; 2018 Apr; 37(1):84. PubMed ID: 29665843
[TBL] [Abstract][Full Text] [Related]
18. Current review of small molecule Ret kinase inhibitors.
Zuercher WJ; Turunen BJ; Lackey KE
Mini Rev Med Chem; 2010 Feb; 10(2):138-46. PubMed ID: 20105131
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A; Takeuchi K; Uenami T; Kawano Y; Tanimoto A; Kaburaki K; Tambo Y; Kudo K; Yanagitani N; Ohyanagi F; Motoi N; Ishikawa Y; Horai T; Nishio M
Lung Cancer; 2016 Mar; 93():43-6. PubMed ID: 26898613
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
